Early Phase 1 Interstitial Lung Disease Trial, Recruiting NCT06853145 Sponsor: University of Virginia Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Early Phase 1 Interstitial Lung Disease Trial, Recruiting

NCT06853145
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been clinically diagnosed with IPF (idiopathic pulmonary fibrosis, a lung condition)
  • People who are able to give their informed consent to participate

Who may not be able to join:

  • People who require continuous oxygen at home
  • People whose blood oxygen level is below 92% on the day of the MRI scan
  • People who are pregnant or breastfeeding
  • People who experience severe anxiety in enclosed spaces (claustrophobia), or who have certain metal implants or devices in their body — such as inner ear implants, aneurysm clips, a pacemaker, metal fragments in the eye, or any implanted device that cannot be confirmed as safe for MRI scanning
  • People with a history of heart defects present from birth, long-term kidney failure, or severe liver scarring (cirrhosis)
  • People whose chest circumference is larger than approximately 42 inches, as this exceeds the size of the MRI equipment used in this trial
  • People who are unable to follow simple instructions or remain still for approximately 10 to 15 seconds
  • People who have had a respiratory infection (such as a chest infection or cold) within the 2 weeks before the MRI scan
  • People with a history of heart attack, stroke, or poorly controlled high blood pressure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: John Kim, MD, University of Virginia

Phone: 4342436074

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measuring the ventilation effect of HXe129 MRI for IPF subjects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov